Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Nuvalent, Inc.NASDAQ: NUVL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $102.23M.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $25.56M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 414.31M USD
- Year-over-year change
- +47.8%
- 4-year CAGR
- +562.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 414.31M | +47.8% |
| FY2024 | 2024-12-31 | 280.37M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 215K | — |
Depreciation & Amortization vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $539.67M USD | -21.3% | +3.4% | 11.4% | |
| LTM Mar 2026 | $102.23M USD | — | — | — | |
| LTM Jun 2026 | $26.8M USD | +40.0% | +38.0% | — | |
| LTM Sep 2026 | $26.62M USD | +11.3% | +28.7% | 5.9% | |
| LTM Sep 2026 | $14.26M USD | -23.6% | -6.9% | 56.7% | |
| LTM Jun 2026 | $12.55M USD | +33.8% | +20.3% | 17.7% | |
| LTM Jun 2026 | $9.94M USD | +16.8% | +27.2% | 1.3% | |
| FY2025 | €1.07M EUR | -2.5% | +30.3% | — | |
| LTM Sep 2026 | $775K USD | -46.5% | -7.2% | 0.3% | |
| Peer median (excluding NUVL) | — | +4.4% | +23.8% | 8.7% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M |
| Selling, General & Admin | 10.26M | 22.38M | 36.25M | 62.59M | 107.34M |
| Operating Expenses | 45.82M | 86.11M | 149.49M | 280.37M | 414.31M |
| Depreciation & Amortization | 215K | 0 | 0 | 280.37M | 414.31M |
| EBITDA | (46.12M) | (81.85M) | (126.22M) | 20.38M | (10.49M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (45.82M) | (86.11M) | (149.49M) | (280.37M) | (414.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 23.27M | 38.32M | 44.74M |
| Interest Expense | 0 | 0 | 23.27M | 0 | 0 |
| Other Income / Expenses | (521K) | 4.25M | 23.27M | 20.38M | (10.49M) |
| Income Before Tax | (46.34M) | (81.85M) | (126.22M) | (259.99M) | (424.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 764K | 585K |
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| EPS (Diluted) | (2.13) | (1.65) | (2.17) | (3.93) | (5.85) |
| Weighted Avg Shares | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
| Weighted Avg Shares (Diluted) | 21.78M | 49.67M | 58.22M | 66.41M | 72.69M |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.